Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells

Cancer Research

Volumn 74, Issue 14, 2014, Pages 3684-3694

  Tu, Megan M ^a   Mahmoud, Ahmad Bakur ^a,c   Wight, Andrew ^a   Mottashed, Amelia ^a   Beĺanger, Simon ^b   Rahim, Mir Munir A ^a   Abou Samra, Elias ^a   Makrigiannis, Andrew P ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c TAIBAH UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; LY49 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; IMMUNE RESPONSE GENE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MELANOMA CELL; METASTASIS; MHC I GENE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; SIGNAL TRANSDUCTION; TRANSGENE; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOLOGIC SURVEILLANCE; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84904256477     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3021     Document Type: Article

References (44)

1. Kiessling R, Klein E, Wigzell H. 'Natural' killer cells in the mouse. I. cytotoxic cells with specificity for mouse moloney leukemia cells. specificity and distribution according to genotype. Eur J Immunol 1975;5:112-7.
2. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. distribution of reactivity and specificity. Int J Cancer 1975;16: 216-29.
3. Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microb Infect 2002;4:1545-58. (Pubitemid 36050824)
4. Pross HF, Lotzova E. Role of natural killer cells in cancer. Nat Immun 1993;12:279-92. (Pubitemid 23297445)
5. Lanier LL. NK cell recognition 2005;23:225-74.
6. Yokoyama WM, Kehn PJ, Cohen DI, Shevach EM. Chromosomal location of the ly-49 (A1, YE1/48) multigene family: Genetic association with the NK 1.1 antigen. J Immunol 1990;145:2353-8. (Pubitemid 20343406)
7. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-8. (Pubitemid 16119452)
8. Leiden JM, Karpinski BA, Gottschalk L, Kornbluth J. Susceptibility to natural killer cell-mediated cytolysis is independent of the level of target cell class I HLA expression. J Immunol 1989;142:2140-7. (Pubitemid 19081575)
9. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. Specificity of HLA class I antigen recognition by human NK clones: Evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type. J Exp Med 1993;178:1321-36. (Pubitemid 23277364)
10. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song Y-, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436:709-13. (Pubitemid 41117274)
11. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005;105:4416-23. (Pubitemid 40720789)
12. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8. (Pubitemid 35363648)
13. Goepel JR, Rees RC, Rogers K, Stoddard CJ, Thomas WEG, Shephard L. Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer 1991;64:880-3.
14. McDougall CJ, Ngoi SS, Goldman IS, Godwin T, Felix J, DeCosse JJ, et al. Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res 1990;50:8023-7.
15. Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, Cadei M, et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998;58:737-42. (Pubitemid 28099486)
16. Cathro HP, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, Frierson HF Jr. Relationship between HLA class i antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother 2010;59:465-72.
17. Han L, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, et al. HLAclass i antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008;14:3372-9.
18. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren G-. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 2008;57:197-206. (Pubitemid 350159921)
19. Belánger S, Tu MM, Rahim MMA, Mahmoud AB, Patel R, Tai L-, et al. Impaired natural killer cell self-education and "missing-self" responses in Ly49-deficient mice. Blood 2012;120:592-602.
20. Liu J, Morris MA, Nguyen P, George TC, Koulich E, Lai WC, et al. Ly49I NK cell receptor transgene inhibition of rejection of H2(b) mouse bone marrow transplants. J Immunol 2000;164:1793-9. (Pubitemid 30108731)
21. Patel R, Bélanger S, Tai L-, Troke AD, Makrigiannis AP. Effect of Ly49 haplotype variance on NK cell function and education. J Immunol 2010;185:4783-92.
22. Kirstein JM, Graham KC, MacKenzie LT, Johnston DE, Martin LJ, Tuck AB, et al. Effect of anti-fibrinolytic therapy on experimental melanoma metastasis. Clin Exp Metastasis 2009;26:121-31.
23. Makrigiannis AP, Rousselle E, Anderson SK. Independent control of Ly49g alleles: Implications for NK cell repertoire selection and tumor cell killing. J Immunol 2004;172:1414-25. (Pubitemid 38116783)
24. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975;35:218-24.
25. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001;61:1095-9. (Pubitemid 32174430)
26. Smyth MJ, Thia KYT, Street SEA, Cretney E, Trapani JA, Taniguchi M, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-8.
27. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001;13:459-63. (Pubitemid 32288543)
28. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002;196:119-27. (Pubitemid 34747317)
29. Adams JM, Harris AW, Pinkert CA. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8. (Pubitemid 16173038)
30. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell- deficient mice. Proc Natl Acad Sci U S A 2000;97:2731-6. (Pubitemid 30159240)
31. Makrigiannis AP, Pau AT, Saleh A, Winkler-Pickett R, Ortaldo JR, Anderson SK. Class I MHC-binding characteristics of the 129/J Ly49 repertoire. J Immunol 2001;166:5034-43. (Pubitemid 32280716)
32. Andrews DM, Sullivan LC, Baschuk N, Chan CJ, Berry R, Cotterell CL, et al. Recognition of the nonclassical MHC class i molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells. Nat Immunol 2012;13:1171-7.
33. Xu H, Chun T, Choi H-, Wang B, Wang C-. Impaired response to listeria in H2-M3-deficient mice reveals a nonredundant role of MHC class ib-specific T cells in host defense. J Exp Med 2006;203:449-59. (Pubitemid 43290853)
34. Festenstein H, Garrido F. Tumour immunology: MHC antigens and malignancy. Nature 1986;322:502-3.
35. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72. (Pubitemid 23117076)
36. O'Sullivan T, Dunn GP, Lacoursiere DY, Schreiber RD, Bui JD. Cancer immunoediting of the NK group 2D ligand H60a. J Immunol 2011; 187:3538-45.
37. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficientmice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008;28:571-80.
38. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419: 734-8. (Pubitemid 35177960)
39. Vey N, Bourhis J-, Boissel N, Bordessoule D, Prebet T, Charbonnier A, et al. Aphase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012;120:4317-23.
40. Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, et al. Aphase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012;120:4324-33.
41. Morabito A, Dozin B, Salvi S, Pasciucco G, Balbi G, Laurent S, et al. Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and ß2-microglobulin downregulation in breast cancer. Hum Immunol 2009;70:492-5.
42. Speetjens FM, De Bruin EC, Morreau H, Zeestraten ECM, Putter H, Van Krieken JH, et al. Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother 2008;57:601-9. (Pubitemid 351641023)
43. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005;117:248-55. (Pubitemid 41377445)
44. Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 2006;55:891-9. (Pubitemid 43673578)